Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 9th World Congress on Bioavailability & Bioequivalence Dubai,UAE.

Day 2 :

Keynote Forum


Australasian Nanoscience and Nanotechnology Initiative, Australia

Keynote: Manufacture of smart nanoliposomes for targeted drug delivery in cancer nanotherapy using “Mozafari Method”

Time : 10:00-10:40

BABE 2018 International Conference Keynote Speaker M. R. MOZAFARI photo

Expert in Nano-biotechnology, Encapsulation & Targeting of Bioactive agents with substantial number of publications, 4 Patents, 5 Books & several Book-chapters. Author  of  the  first  book  on  Nanoliposomes;  completed  many  industrial  research  projects,  developed  methods  including  “Mozafari  Method”  for  large-scale manufacture of controlled-release carrier systems without using toxic agents. Recently introduced a novel technology for the encapsulation and delivery of bioactive compounds called "Tocosome".


Nanoliposomes, or nanoscale bilayer lipid vesicles, are one of the most applied  bioactive  delivery  technologies.  They  have  many  advantages over  conventional  dosage  forms  including  the  potential to  enhance  the bioavailability  of  the  drug  and  provide  drug  targeting.  Targeted delivery of therapeutic agents has received considerable attention due to  its  significant  role  in  improving  therapeutic  efficacy  and  reducing side  effects.  5-fluorouracil  (5FU)  is  an  anticancer  drug  with  short  half- life    and    high    side    effects    that    limit    its    clinical    applications. Consequently,  cancer  treatment  using  5FU  can  benefit  significantly employing  nanoliposome  technology.  This  entry  aims  to  present  our recent findings on the evaluation of anticancer potential of folate and tumor       associated       carbohydrate       antigens       (TACA)-targeted nanoliposomal  5FU  on  different  carcinoma  cells.  Nanoliposomes  and PEGylated    nanoliposomes    (ca.    95-130nm)    were    prepared    by Mozafari    method,    without    employing    potentially    toxic    solvents, detergents or harsh treatments such as homogenization or sonication at

40-60  deg.  C  and  less  than  1000  rpm  turbulence  (as  depicted  in  the Image). Drug encapsulation efficiencies between ca. 55% to 70% were obtained.  Nanoliposomal  formulations  were  thoroughly  characterized for    their    surface    chemistry,    particle    size,    zeta    potential,    PDI, encapsulation  efficiency,  stability  and  release  profiles.  The  effect  of the “smart nanoliposomes” on the induction of apoptosis and cell cycle arrest   was   studied   by   flow   cytometry.   Anticancer   activity   was evaluated by the Neutral Red and MTT assays. The cytotoxicity of the formulations    against    cultured    cells    was    significantly    increased compared   to   the   controls.   Flow   cytometry   and   annexin-V   analysis indicated  that  “smart  nanoliposomes”  encapsulating  5FU  effectively induced  apoptosis  and  cell-cycle  arrest  in  the  cultured  cells.  Overall, research  findings  indicated  that  “smart  nanoliposomes”  are  promising formulations for targeted drug delivery to tumor cells.